Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Disease
|
|
- Kristina Woods
- 5 years ago
- Views:
Transcription
1 1282 SHIOMI H et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society Cardiovascular Intervention Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Disease 5-Year Outcome From CREDO-Kyoto PCI/CABG Registry Cohort-2 Hiroki Shiomi, MD; Takeshi Morimoto, MD, PhD; Yutaka Furukawa, MD; Yoshihisa Nakagawa, MD; Ryuzo Sakata, MD; Hitoshi Okabayashi, MD; Michiya Hanyu, MD; Mitsuomi Shimamoto, MD; Noboru Nishiwaki, MD; Tatsuhiko Komiya, MD; Takeshi Kimura, MD on behalf of the CREDO-Kyoto PCI/CABG registry cohort-2 investigators Background: Studies evaluating long-term ( 5 years) outcome of percutaneous coronary intervention (PCI) compared with coronary artery bypass grafting (CABG) in patients with unprotected left main coronary artery disease (ULMCAD) are still limited, despite concerns for late adverse events after drug-eluting stents implantation. Methods and Results: We identified 1,004 patients with ULMCAD (PCI: n=364, CABG: n=640) among 15,939 patients with first coronary revascularization enrolled in the CREDO-Kyoto PCI/CABG registry cohort-2. The primary outcome measure in the current analysis was a composite of death, myocardial infarction, and stroke (death/mi/ stroke). The cumulative 5-year incidence of and the adjusted risk for death/mi/stroke were significantly higher in the PCI group than in the CABG group (34.5% vs. 24.1%, log-rank P<0.001, adjusted hazard ratio (HR): 1.48 [95% confidence interval (CI): , P=0.02]). The adjusted risks for all-cause death was not significantly different between the 2 groups. Regarding the stratified analysis by the SYNTAX score, the adjusted risk for death/mi/stroke was not significantly different between the 2 groups in patients with low (<23) or intermediate (23 33) SYNTAX score, whereas it was significantly higher in the PCI group than in the CABG group in patients with high ( 33) SYNTAX score. Conclusions: CABG as compared with PCI was associated with better long-term outcome in patients with ULMCAD, especially those with high anatomical complexity. (Circ J 2015; 79: ) Key Words: Coronary artery bypass grafting; Drug-eluting stents; Left main disease; Percutaneous coronary intervention Several studies have reported favorable short- and mid-term outcomes of percutaneous coronary intervention (PCI) using drug-eluting stents (DES) in patients with unprotected left main coronary artery disease (ULMCAD), leading to the update of clinical guidelines in which PCI is regarded as an acceptable alternative to coronary artery bypass grafting (CABG) in selected patients with ULMCAD. 1 8 On the other hand, late adverse events beyond 1 year after DES implantation, such as very late stent thrombosis (VLST) and late targetlesion revascularization (TLR), are reported to be a continuous hazards up to 5 years after DES implantation and still a major concern after PCI using DES Studies evaluating long-term Received January 12, 2015; revised manuscript received February 22, 2015; accepted February 23, 2015; released online March 30, 2015 Time for primary review: 15 days Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto (H.S., T. Kimura); Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya (T.M.); Division of Cardiology, Kobe City Medical Center General Hospital, Kobe (Y.F.); Division of Cardiology, Tenri Hospital, Tenri (Y.N.); Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto (R.S.); Department of Cardiovascular Surgery, Iwate Medical University, Morioka (H.O.); Division of Cardiovascular Surgery, Kokura Memorial Hospital, Kitakyushu (M.H.); Division of Cardiovascular Surgery, Shizuoka City Shizuoka Hospital, Shizuoka (M.S.); Division of Cardiovascular Surgery, Nara Hospital, Kinki University Faculty of Medicine, Ikoma (N.N.); and Division of Cardiovascular Surgery, Kurashiki Central Hospital, Kurashiki (T. Komiya), Japan Mailing address: Takeshi Kimura, MD, Department of Cardiovascular of Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto , Japan. taketaka@kuhp.kyoto-u.ac.jp ISSN doi: /circj.CJ All rights are reserved to the Japanese Circulation Society. For permissions, please cj@j-circ.or.jp
2 5-Year Outcome in Patients With ULMCAD 1283 Figure 1. Comparison of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in unprotected left main coronary artery disease: study flow chart. ( 5 years) outcome of PCI compared with CABG in patients with ULMCAD are still limited We previously reported 3-year outcome in patients with ULMCAD from the Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/CABG registry cohort-2, demonstrating that (1) 3-year clinical outcome of PCI was comparable with that of CABG in terms of serious cardiovascular events in patients with ULMCAD and (2) the risk for serious cardiovascular events was not significantly different between PCI and CABG in patients with low or intermediate SYNTAX score, but was markedly higher after PCI as compared with CABG in patients with high SYNTAX score. 16 In the current report, we extended the follow-up to evaluate longer-term ( 5 years) outcome of PCI compared with CABG in patients with ULMCAD in real-world clinical practice. Editorial p 1201 Methods Study Population As previously described in detail, the CREDO-Kyoto PCI/ CABG registry cohort-2 is a physician-initiated non-company sponsored multicenter registry enrolling consecutive patients undergoing their first coronary revascularization in 26 centers in Japan between January 2005 and December The relevant ethics committees in all 26 participating centers (Appendix S1) approved the research protocol. Because of the retrospective enrollment, the requirement for written informed consent from the patients was waived; however, we excluded patients who refused participation in the study when contacted for follow-up. This strategy is concordant with the guidelines of the Japanese Ministry of Health, Labor and Welfare. Among the 15,939 patients enrolled in the registry, the study population for the current analysis consisted of 1,004 patients with ULMCAD (PCI: 364 patients, CABG: 640 patients), excluding those patients refusing study participation (n=99), concomitant non-coronary surgery (n=609), acute myocardial infarction (MI) presentation (n=4,892), and without ULMCAD (n=9,336) (Figure 1). Definitions and Endpoints The primary outcome measure in the current study was a composite of death, MI, and stroke. The secondary outcome measures included cardiac death, sudden cardiac death, noncardiac death, MI, stroke, hospitalization for heart failure, major bleeding, any coronary revascularization, and ischemia-driven coronary revascularization. Death was regarded as cardiac in origin unless an obvious non-cardiac cause could be identified. Any death during the index hospitalization for coronary revascularization was regarded as cardiac death. MI was defined according to the definition in the Arterial Revascularization Therapy Study. 19 Stroke was defined as ischemic or hemorrhagic stroke either occurring during the index hospitalization or requiring hospitalization with symptoms lasting >24 h. Hospitalization for heart failure was defined as hospitalization for worsening heart failure requiring intravenous drug therapy. Bleeding was defined according to the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) classification; 20 GUSTO moderate or severe bleeding was adjudicated as a bleeding event. Any coronary revascularization was defined as either PCI or CABG
3 1284 SHIOMI H et al. for any reason. Scheduled staged coronary revascularization procedures performed within 3 months of the initial procedure were not regarded as follow-up events, but were included in the index procedure. Detailed definitions of baseline clinical characteristics and endpoints were reported previously. 16,17,21,22 Data Collection for Baseline Characteristics and Follow-up Events Experienced clinical research coordinators from an independent clinical research organization (Research Institute for Production Development, Kyoto, Japan; Appendix S2) collected baseline clinical, angiographic and procedural characteristics from hospital charts or hospital databases according to prespecified definitions. Collection of follow-up information was mainly conducted through review of inpatient and outpatient hospital charts by the clinical research coordinators, and additional follow-up information was collected through contact with patients, relatives and/or referring physicians by mail with questions regarding vital status, subsequent hospitalizations, and status of antiplatelet therapy. Death, MI, and stroke were Table 1. Comparison of the Baseline Characteristics of the PCI and CABG Groups PCI (n=364) CABG (n=640) P value Clinical characteristics Age (years) 71.4± ± years* 151 (41%) 208 (33%) Male* 258 (71%) 490 (77%) Body mass index <25.0* 270 (74%) 467 (73%) 0.68 Unstable angina 51 (14%) 71 (11%) 0.18 Hypertension* 312 (86%) 542 (85%) 0.66 Diabetes mellitus* 154 (42%) 291 (45%) 0.33 On insulin therapy 34 (9.3%) 93 (15%) 0.02 Current smoking* 78 (21%) 157 (25%) 0.26 LDL cholesterol (mg/dl) 117±34 112± Heart failure* 76 (21%) 131 (20%) 0.88 Ejection fraction 40% 34 (12%) 56 (9.5%) 0.30 Mitral regurgitation grade 3/4* 25 (6.9%) 17 (2.7%) Prior MI* 70 (19%) 105 (16%) 0.26 Prior stroke (symptomatic)* 54 (15%) 75 (12%) 0.16 Peripheral vascular disease* 45 (12%) 76 (12%) 0.82 egfr <30, without hemodialysis* 19 (5.2%) 38 (5.9%) 0.63 Hemodialysis* 25 (6.9%) 44 (6.9%) Anemia (hemoglobin <11.0 g/dl)* 72 (20%) 128 (20%) 0.93 Thrombocytopenia (platelets < )* 3 (0.8%) 19 (3.0%) 0.02 Chronic obstructive pulmonary disease* 12 (3.3%) 17 (2.7%) 0.56 Liver cirrhosis* 9 (2.5%) 19 (3.0%) 0.64 Malignancy* 58 (16%) 69 (11%) 0.02 Procedural characteristics No. of target lesions or anastomoses 2.00± ±1.04 <0.001 Target of proximal LAD* 174 (48%) 451 (70%) <0.001 Target of chronic total occlusion* 45 (12%) 166 (26%) <0.001 Emergency procedure 34 (9.3%) 50 (7.8%) 0.40 Extent of coronary artery disease <0.001 Isolated ULMCA disease 31 (8.5%) 57 (8.9%) ULMCA+1-vessel disease 89 (24.5%) 108 (16.9%) ULMCA+2-vessel disease 131 (36.0%) 182 (28.4%) ULMCA+3-vessel disease 113 (31.0%) 293 (45.8%) SYNTAX score 26.5 (21 34) 30 (22 40) <0.001 Low < (34.2%) 154 (26.8%) <0.001 Intermediate (36.7%) 177 (30.8%) High (29.1%) 243 (42.3%) Total no. of stents 2.79±1.70 Total stent length (mm) 58.8±41.1 Stent use 356 (98%) DES use 276 (78%) ITA use 629 (98%) Off pump 414 (65%) (Table 1 continued the next page.)
4 5-Year Outcome in Patients With ULMCAD 1285 PCI (n=364) CABG (n=640) P value Baseline medications Antiplatelet therapy Thienopyridine 361 (99%) 72 (11%) <0.001 Ticlopidine 315 (87%) 67 (94%) 0.07 Clopidogrel 46 (13%) 4 (5.6%) Aspirin 360 (99%) 632 (99%) 0.83 Cilostazol* 45 (12%) 41 (6.4%) Other medications Statins* 184 (51%) 199 (31%) <0.001 β-blockers* 109 (30%) 174 (27%) 0.35 ACEI/ARB* 190 (52%) 211 (33%) <0.001 Nitrates* 170 (47%) 230 (36%) Calcium-channel blockers* 170 (47%) 332 (52%) 0.12 Nicorandil* 94 (26%) 277 (43%) <0.001 Warfarin* 30 (8.2%) 244 (38%) <0.001 Proton-pump inhibitors* 92 (25%) 263 (41%) <0.001 Histamine type-2 receptor blockers* 77 (21%) 204 (32%) <0.001 *Risk-adjusting variables selected for Cox proportional hazard models. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; DES, drug-eluting stents; egfr, estimated glomerular filtration rate; ITA, internal thoracic artery; LAD, left anterior descending coronary artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; ULMCA, unprotected left main coronary artery. adjudicated by the clinical event committee (Appendix S3). Median follow-up duration for the surviving patients was 1,959 (inter-quartile range [IQR]: 1,695 2,200) days. Complete 1-, 3-, and 5-year clinical follow-up information was obtained for 97.9%, 96.3%, and 72.5% of patients, respectively. Statistical Analysis Categorical variables were presented as number and percentage and compared with the chi-square test. Continuous variables were expressed as mean ± standard deviation (SD) or median with IQR. Continuous variables were compared using Student s t-test or the Wilcoxon rank sum test based on their distributions. Cumulative incidence was estimated by the Kaplan-Meier method and differences were assessed with the log-rank test. The effects of PCI relative to CABG for individual endpoints were expressed as hazard ratios (HR) with 95% confidence intervals (CI). We estimated the HR by Cox proportional hazard models adjusting for 30 clinically relevant factors listed in Table 1. Continuous variables were dichotomized by clinically meaningful reference values or median values. Proportional hazard assumptions for potential independent risk-adjusting variables were assessed on the plots of log (time) vs. log [ log (survival)] stratified by the variable, and the assumptions were verified to be acceptable for all the variables. We incorporated the 26 participating centers in the Cox proportional hazard models as the stratification variable. The unadjusted and adjusted risks of PCI relative to CABG for the primary outcome measure were evaluated in each SYNTAX score category as a subgroup analysis. In addition to the modes of coronary revascularization (PCI vs. CABG), variables with P<0.05 in the previously described full model were included in the multivariable models for the subgroup analysis, reflecting our preference for parsimonious models to avoid over-fitting. All statistical analyses were conducted using JMP 8.0 software (SAS Institute Inc, Cary, NC, USA) and SAS 9.2 (SAS Institute Inc). All reported P values were 2-tailed, and P<0.05 was considered statistically significant. Results Baseline Characteristics The study population reflected real-world clinical practice, including large proportions of patients with advanced age, diabetes mellitus, past history of heart failure, prior stroke, and renal insufficiency (Table 1). Compared with the CABG group, the PCI group included more elderly patients and those with malignancy and severe mitral regurgitation. Patients with diabetes on insulin therapy and thrombocytopenia were more common in the CABG group than in the PCI group (Table 1). Regarding the lesion characteristics, approximately twothirds of the patients in the entire cohort had multivessel coronary artery disease in addition to ULMCAD. The CABG group included more patients with complex coronary anatomy represented by the SYNTAX score (mean SYNTAX score: 26.5 vs. 30, P<0.001) and greater numbers of target lesions or anastomoses (2.00±1.03 vs. 3.09±1.04, P<0.001) (Table 1). In the PCI group, the majority of patients received stents (98%) and 78% of patients received at least 1 DES. DES were used for ULMCAD in 69% of patients. In the CABG group, the vast majority of patients received at least 1 internal thoracic artery bypass graft (98%), and the prevalence of off-pump CABG was high (65%). The patients in the PCI group more often experienced evidence-based medicine such as statins and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker compared with those in the CABG group (Table 1). Long-Term Clinical Outcome: PCI vs. CABG The cumulative 5-year incidence of death/mi/stroke (primary outcome measure) in the PCI group was significantly higher than that in the CABG group (34.5% vs. 24.1%, log-rank P<0.001) (Figure 2, Table 2). After adjusting for confounders, the risk for death/mi/stroke remained significantly higher in the PCI group than in the CABG group (adjusted HR: 1.48, 95% CI: , P=0.02) (Table 2). Regarding survival outcome, the adjusted risk for all-cause death was not significantly
5 1286 SHIOMI H et al. Figure 2. Kaplan-Meier event curves for (A) death/mi/stroke, and (B) all-cause death. PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MI, myocardial infarction. Table 2. Crude and Adjusted 5-Year Clinical Outcomes: PCI vs. CABG PCI (n=364) CABG (n=640) Endpoint No. of events No. of events (Incidence) (Incidence) Crude HR (95% CI) P value Adjusted HR (95% CI) P value All-cause death 88 (25.3%) 109 (18.0%) 1.54 ( ) ( ) 0.16 Cardiac death 44 (13.2%) 41 (7.2%) 1.99 ( ) < ( ) 0.02 Sudden cardiac death 15 (4.9%) 9 (1.6%) 2.71 ( ) Non-cardiac death 44 (13.9%) 68 (11.7%) 1.26 ( ) ( ) 0.95 MI 25 (7.7%) 19 (3.3%) 2.53 ( ) ( ) 0.04 Stroke 27 (8.6%) 42 (7.1%) 1.32 ( ) ( ) 0.81 Hospitalization for heart failure 43 (13.4%) 51 (9.0%) 1.65 ( ) ( ) 0.21 Major bleeding 56 (17.0%) 350 (54.9%) 0.25 ( ) < ( ) <0.001 Major bleeding beyond 30 days after procedure 41 (13.1%) 62 (10.7%) 1.32 ( ) ( ) 0.52 Any coronary revascularization 148 (45.7%) 84 (14.3%) 3.81 ( ) < ( ) <0.001 Ischemia-driven coronary revascularization 74 (23.8%) 35 (6.2%) 4.18 ( ) < ( ) <0.001 Death/MI/stroke 121 (34.5%) 147 (24.1%) 1.66 ( ) < ( ) 0.02 CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1. different between the 2 groups (adjusted HR: 1.32, 95% CI: , P=0.16), although the cumulative 5-year incidence of all-cause death was significantly higher in the PCI group than in the CABG group (25.3% vs. 18.0%, log-rank P=0.001) (Figure 2, Table 2). The cumulative 5-year incidences of and the adjusted risks for cardiac death, MI, and any coronary revascularization were significantly higher in the PCI group than in the CABG group (adjusted HR: 2.00 [95% CI: , P=0.02], adjusted HR: 2.25 [95% CI: , P=0.04], and adjusted HR: 4.31 [95% CI: , P<0.001], respectively) (Table 2). The adjusted risk for hospitalization for heart fail- ure was not significantly different between the 2 groups (HR: 1.43, 95% CI: , P=0.21). The risk for major bleeding beyond 30 days after procedure was also not significantly different between the 2 groups (HR: 1.18, 95% CI: , P=0.52), although the overall risk for major bleeding, including bleeding events during the perioperative period, was significantly higher in the CABG group than in the PCI group (HR: 0.20, 95% CI: , P<0.001) (Table 2). SYNTAX Score and Clinical Outcome: PCI vs. CABG The SYNTAX scores were available for 931 patients (92.7%).
6 5-Year Outcome in Patients With ULMCAD 1287 Figure 3. Kaplan-Meier event curves comparing PCI with CABG for death/mi/stroke stratified by SYNTAX score tertile. (A) Low SYNTAX score category (<23), (B) intermediate SYNTAX score category (23 32), (C) high SYNTAX score category ( 33). PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MI, myocardial infarction. The median SYNTAX score was significantly higher in the CABG group than in the PCI group (30 vs. 26.5, P<0.001) (Table 1). The cumulative 5-year incidence of the primary outcome measure (death/mi/stroke) was not significantly different between the 2 groups in patients with low (<23) SYNTAX score (31.9% vs. 24.1%, log-rank P=0.16) (Figure 3). In patients with intermediate (23 33) and high ( 33) SYNTAX score, however, the measure was significantly higher in the PCI group than in the CABG group (35.8% vs. 21.8%, log-rank P<0.001, and 37.3% vs. 27.5%, log-rank P=0.009, respectively) (Figure 3). After adjusting for confounders, the risk for death/mi/stroke was not significantly different between the 2 groups for patients with low and intermediate SYNTAX scores (adjusted HR: 1.76 [95% CI: , P=0.0504], and adjusted HR: 1.53 [95% CI: , P=0.14], respectively), whereas it was signifi-
7 1288 SHIOMI H et al. cantly higher in the PCI group than in the CABG group for patients with high SYNTAX score (adjusted HR: 2.09, 95% CI: , P=0.004). Discussion The main findings of the current analysis were as follows: (1) CABG as compared with PCI was associated with better longterm outcome in patients with ULMCAD in real-world clinical practice, and (2) consistent with our previous 3-year report and the SYNTAX randomized trial, the long-term risk for serious cardiovascular events was not significantly different between PCI and CABG in patients with low or intermediate SYNTAX scores, but was markedly higher after PCI as compared with CABG in patients with high SYNTAX score. Extended 5-year follow-up in the current study made it possible to demonstrate an advantage of CABG over PCI in terms of the long-term outcome of patients with ULMCAD in realworld clinical practice, which could not be demonstrated in our previous 3-year follow-up results. In fact, late adverse events occurring beyond 1 year after DES implantation, such as VLST and late TLR, are major concerns of DES, and have been reported to continue occurring for up to 5 years at least However, studies evaluating long-term ( 5 years) outcomes of PCI compared with CABG in patients with ULMCAD are still limited The long-term risks for both MI and repeat coronary revascularization were significantly lower after CABG than after PCI in the current study. Subgroup analysis of ULMCAD patients in the SYNTAX randomized trial recently reported comparable 5-year cardiovascular outcomes for PCI and CABG. 13 The randomized control trial is the gold standard for comparing treatments, but generally enrolls selective patients without high risk profiles. On the other hand, observational study reflects real-world clinical practice, where there are many patients considered high risk such as the elderly, diabetics, and those with surgical ineligibility. The MAIN-COMPARE registry and several other studies reported comparable long-term cardiovascular outcomes for PCI and CABG, except for excess risk with PCI for repeat revascularization in patients with ULMCAD. 12,14,15 Consistent with the current study result, however, the RERIC and REAL investigators reported the long-term risks for death and MI as significantly lower after CABG than after PCI in patients with ULMCAD. 23 The reason for this discrepancy between studies might be the different characteristics of the patient populations in each study, especially differences in the proportions of high-risk patients with such as the elderly, diabetics, and those with a past history of heart failure, or complex multivessel disease. Consistent with both our previous 3-year follow-up results and the 5-year follow-up results from the SYNTAX randomized trial, the current 5-year follow-up study in real-world clinical practice confirmed the utility of the SYNTAX score for risk stratification and selection of mode of revascularization procedure, supporting the current updated clinical guidelines for ULMCAD. 5 7,13,16 Therefore, in ULMCAD patients with relatively less anatomical complexity, represented by a low or intermediate SYNTAX score, PCI using DES is a reasonable alternative to CABG in real-world clinical practice. On the other hand, CABG still remains the preferable treatment for ULMCAD patients with high anatomical complexity (ie, high SYNTAX score or complex multivessel disease), because the clinical outcome after CABG is not affected by anatomical complexity. Study Limitations First and most importantly, the observational study design precludes drawing definitive conclusions regarding the superiority of either PCI or CABG, because of selection bias and unmeasured confounders, despite appropriate statistical adjustment for potential confounders. Second, the number of patients enrolled was still small, although longer-term follow-up made it possible to demonstrate an advantage of CABG over PCI in the entire cohort. Finally, because patient demographics, practice patterns, and clinical outcomes in patients undergoing PCI and CABG in Japan may be different from those outside Japan, generalizing these results to populations outside Japan should be done with caution. Conclusions CABG as compared with PCI was associated with better longterm outcome for patients with ULMCAD, especially those with high anatomical complexity. Acknowledgments We appreciate the support and collaboration of the co-investigators participating in the CREDO-Kyoto PCI/CABG Registry Cohort-2. We are indebted to the outstanding effort of the clinical research coordinators for data collection. Disclosures Conflict of Interest: None of the authors has any conflict of interest to disclose. Funding Sources: This study was supported by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. References 1. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronaryartery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxeleluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010; 121: Seung KB, Park DW, Kim YH, Lee SW, Lee CW, Hong MK, et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008; 358: Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364: Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: e574 e651, doi: / CIR.0b013e31823ba Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC), the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: Shiomi H, Tamura T, Niki S, Tada T, Tazaki J, Toma M, et al. Interand intra-observer variability for assessment of the synergy between percutaneous coronary intervention with TAXUS and Cardiac surgery (SYNTAX) score and association of the SYNTAX score with clinical
8 5-Year Outcome in Patients With ULMCAD 1289 outcome in patients undergoing unprotected left main stenting in the real world. Circ J 2011; 75: Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: Five-year outcome of the j-cypher Registry. Circulation 2012; 125: Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, et al. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-cypher Registry). Am J Cardiol 2010; 106: Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, et al. Late adverse events after implantation of sirolimuseluting stent and bare-metal stent: Long-term (5 7 years) follow-up of the coronary revascularization demonstrating outcome study-kyoto registry cohort-2. Circ Cardiovasc Interv 2014; 7: Chieffo A, Magni V, Latib A, Maisano F, Ielasi A, Montorfano M, et al. 5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions: The Milan experience. JACC Cardiovasc Interv 2010; 3: Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the SYNTAX trial. Circulation 2014; 129: Park DW, Kim YH, Yun SC, Lee JY, Kim WJ, Kang SJ, et al. Longterm outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol 2010; 56: Park DW, Seung KB, Kim YH, Lee JY, Kim WJ, Kang SJ, et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol 2010; 56: Shiomi H, Morimoto T, Hayano M, Furukawa Y, Nakagawa Y, Tazaki J, et al. Comparison of long-term outcome after percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol 2012; 110: Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, et al. Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan. Cardiovasc Interv Ther 2011; 26: Campos CM, van Klaveren D, Iqbal J, Onuma Y, Zhang YJ, Garcia- Garcia HM, et al. Predictive performance of SYNTAX score II in patients with left main and multivessel coronary artery disease: Analysis of CREDO-Kyoto registry. Circ J 2014; 78: Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: The GUSTO investigators. N Engl J Med 1993; 329: Tazaki J, Shiomi H, Morimoto T, Imai M, Yamaji K, Sakata R, et al. Three-year outcome after percutaneous coronary intervention and coronary artery bypass grafting in patients with triple-vessel coronary artery disease: Observations from the CREDO-Kyoto PCI/CABG registry cohort-2. EuroIntervention 2013; 9: Nishino T, Furukawa Y, Kaji S, Ehara N, Shiomi H, Kim K, et al. Distinct survival benefits of angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction. Circ J 2013; 77: Fortuna D, Nicolini F, Guastaroba P, De Palma R, Di Bartolomeo S, Saia F, et al. Coronary artery bypass grafting vs percutaneous coronary intervention in a real-world setting: A comparative effectiveness study based on propensity score-matched cohorts. Eur J Cardiothorac Surg 2013; 44: e16 e24, doi: /ejcts/ezt197. Supplementary Files Supplementary File 1 Appendix S1 Appendix S2 Appendix S3 Please find supplementary file(s);
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationCoronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies
Review J Jpn Coron Assoc 2015; 21: 267-271 Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies Hiroki Shiomi, Takeshi Kimura
More informationPrediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores
ORIGINAL RESEARCH Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores Masahiro Natsuaki, MD; Takeshi Morimoto, MD; Kyohei
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationComparison of Three-year Outcome after PCI and CABG in Triple Vessel Coronary Artery Disease. CREDO-Kyoto PCI/CABG Registry Cohort-2
Comparison of Three-year Outcome after PCI and CABG in Triple Vessel Coronary Artery Disease Stratified analysis by the SYNTAX Score CREDO-Kyoto PCI/CABG Registry Cohort-2 Hiroki Shiomi, Junichi Tazaki,
More informationAccepted Manuscript. Coronary dialysis patients: CABG or PCI? A complex question for a complex scenario
Accepted Manuscript Coronary dialysis patients: CABG or PCI? A complex question for a complex scenario Francesco Formica, MD, Stefano D Alessandro, MD, FECTS. PII: S0022-5223(18)32554-6 DOI: 10.1016/j.jtcvs.2018.09.050
More informationLong-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery
Journal of Geriatric Cardiology (2017) 14: 254 260 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected
More information7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET) Hiroki Shiomi, MD Kyoto University Graduate School of Medicine
More informationThe ad hoc percutaneous coronary intervention
458 TOYOTA T et al. Circ J 2017; 81: 458 467 ORIGINAL ARTICLE doi: 10.1253/circj.CJ-16-0987 Cardiovascular Intervention Ad hoc vs. Non-ad hoc Percutaneous Coronary Intervention Strategies in Patients With
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More informationORIGINAL ARTICLE. Ischemic Heart Disease
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Ischemic Heart Disease Distinct Survival Benefits of Angiotensin-Converting Enzyme Inhibitors/Angiotensin
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationJournal of the American College of Cardiology Vol. 57, No. 21, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.033
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationLeft Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationNOBLE and EXCEL: The debate for excellence in dealing with left main stenosis
O P E N A C C E S S 1 Aswan Heart Centre, Aswan, Egypt 2 Sultan Qaboos University Hospital, Muscat, Sultanate of Oman 3 Cairo University, Cairo, Egypt *Email: hatem.hosny@aswanheartcentre.com Lessons from
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationPredictive value of SYNTAX score II for clinical outcomes in octogenarian undergoing percutaneous coronary intervention
Journal of Geriatric Cardiology (2016) 13: 733 739 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Predictive value of SYNTAX score II for clinical outcomes in octogenarian undergoing
More informationORIGINAL ARTICLE. Introduction
ORIGINAL ARTICLE Vasc Fail 2018; 2: 25-31 A Cost-benefit Analysis of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting using Reimbursement Data of Japan: A Single-center Pilot Study
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationSirolimus-Eluting Stent Implantation for Ostial Left Anterior Descending Coronary Artery Lesions Three-Year Outcome From the j-cypher Registry
Sirolimus-Eluting Stent Implantation for Ostial Left Anterior Descending Coronary Artery Lesions Three-Year Outcome From the j-cypher Registry Koichi Kishi, MD; Takeshi Kimura, MD; Takeshi Morimoto, MD;
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationCoronary Revascularization in Patients With Liver Cirrhosis
Coronary Revascularization in Patients With Liver Cirrhosis Akira Marui, MD, PhD, Takeshi Kimura, MD, PhD, Shiro Tanaka, PhD, Senri Miwa, MD, PhD, Kazuhiro Yamazaki, MD, PhD, Kenji Minakata, MD, PhD, Tomohiro
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationWhen should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER
When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial
More informationDeclaration of conflict of interest NONE
Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationIncidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction
Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction Sungmin Lim, Yoon Seok Koh, Hee Yeol Kim, Ik Jun Choi, Eun Ho Choo, Jin Jin Kim, Mineok
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationAdecade ago, many cardiac surgeons believed
CABG for Multivessel CAD Recent studies show that CABG is still preferred over PCI for most patients. BY SUBHASIS CHATTERJEE, MD; JOHN C. ALEXANDER, MD; AND PAUL J. PEARSON, MD, PHD Adecade ago, many cardiac
More informationOptimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES LATE Trial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationTrial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Seung-Jung Park, MD, PhD On behalf of the BEST investigators Professor of Medicine, University of Ulsan College of
More informationCoronary Artery Bypass Grafting vs. Drug-Eluting Stent Implantation for Multivessel Disease in Patients with Chronic Kidney Disease
Original Article https://doi.org/1.47/kcj.216.439 Print ISSN 1738-552 On-line ISSN 1738-5555 Korean Circulation Journal Coronary Artery Bypass Grafting vs. Drug-Eluting Stent Implantation for Multivessel
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationLong-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease
Journal of the American College of Cardiology Vol. 56, No. 17, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.03.097
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationΔημήτριος Αγγοσράς, FETCS
ΣΕΜΙΝΑΡΙΟ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Δημήτριος Αγγοσράς, FETCS Επίκοσρος Καθηγηηής Καρδιοτειροσργικής Ιαηρική Πανεπιζηημίοσ Αθηνών Πανεπιζηημιακό Γενικό Νοζοκομείο Αηηικόν Randomized Controlled Trials (RCTs) Why
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationOUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.
INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Maquet, Inc.,- unpaid consultant Cordis, Inc.,- unpaid consultant Boston Scientific, Inc.,- travel expenses paid for Syntax
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationKurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report
World Journal of Cardiovascular Diseases, 2014, 4, 483-491 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjcd http://dx.doi.org/10.4236/wjcd.2014.49058 Kurdistan Technique for the
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationAbstract. Roman S Tarasov and Vladimir I Ganyukov. Research Institute for Complex Issues of Cardiovascular Diseases, Russia
Chapter 2 Prognostic Role of Initial and Residual Syntax Score in Patients with ST-Segment Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention Roman S Tarasov and Vladimir
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationCoronary Artery Disease
Coronary Artery Disease Incidence and Outcome of Surgical Procedures After Coronary Artery Bypass Grafting Compared With Those After Percutaneous Coronary Intervention A Report From the Coronary Revascularization
More informationRelations of Interest
Relations of Interest Consulting Fees on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the Cardiovascular Research Center Aalst and several pharmaceutical and device
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationMise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationPercutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE combined cardiology and cardiac surgery perspective
Perspective Percutaneous coronary intervention in left main disease: SYNTAX, PRECOMBAT, EXCEL and NOBLE combined cardiology and cardiac surgery perspective Duk-Woo Park 1, Jung-Min Ahn 1, Seung-Jung Park
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationTRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE. Jonathan Poveda CLINICA BIBLICA 2015
TRATAMIENTO INVASIVO ENFERMEDAD ISQUEMICA ESTABLE Jonathan Poveda CLINICA BIBLICA 2015 COURAGE First coronary angioplasty lesion (circles) two days before (A), immediately after (B), and one month after
More informationChapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials DEBDATTA BHATTACHARYYA AYAN KAR The incidence of angiographically significant left main stenosis described in various studies has
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationOsler Journal Club Outcomes Research
Osler Journal Club Outcomes Research Malenka DJ, et al. Outcomes Following Coronary Stenting in the Era of Bare-Metal vs. the Era of Drug- Eluting Stents. JAMA 2008; 299(24):2868-2876 Mentor: Dr. Boulware
More informationMedicine OBSERVATIONAL STUDY
Medicine OBSERVATIONAL STUDY It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent Ju-Youn Kim,
More informationDavid E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California
38 RCTs 18,000 pts Identifying the Optimal Duration of DAPT Less is More, More or Less David E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California kandzari.david@scrippshealth.org
More informationComparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease
Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease Jeong Hoon Yang, MD, Hyeon-Cheol Gwon, MD, Soo Jin Cho, MD, Joo
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More information